3/2/2017 1 David T. Jones, M.D. Associate Consultant, Department of Neurology, Mayo Clinic Assistant Professor of Neurology and Radiology, Mayo Clinic College of Medicine NEUROIMAGING IN ALZHEIMER’S DISEASE: MEASURING MINDS AND MOLECULES IMAGING BIOMARKERS • A biological marker of some state. • National Institutes of Health Biomarkers Definitions Working Group: • “[A] characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” • How can we use biomarkers? • Diagnosis • Prognosis • Monitor progression • Monitor disease response to therapeutic interventions • Understand pathophysiology (i.e. the cause of the disease) WHAT DO GOOD BIOMARKERS LOOK LIKE
13
Embed
Neuroimaging in the ADRC and mCSA - alz. · PDF fileMayo Clinic Study of Aging (MCSA) (PI: Ron Petersen) Aging and Dementia Imaging Research Laboratory (PI: Cliff Jack) Title: Neuroimaging
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
3/2/2017
1
David T. Jones, M.D.
Associate Consultant, Department of Neurology, Mayo Clinic
Assistant Professor of Neurology and Radiology, Mayo Clinic College of Medicine
NEUROIMAGING IN ALZHEIMER’S DISEASE:
MEASURING MINDS AND MOLECULES
IMAGING BIOMARKERS
• A biological marker of some state.
• National Institutes of Health Biomarkers Definitions Working Group:
• “[A] characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention.”
• How can we use biomarkers?
• Diagnosis
• Prognosis
• Monitor progression
• Monitor disease response to therapeutic interventions
• Understand pathophysiology (i.e. the cause of the disease)
Stage 1 Stage 2 Stage 3 MCI Mild AD Moderate AD Severe AD
Aβ
Degeneration
Tau-PET
Amyloid-PET
PART
3/2/2017
11
MEASURING MINDS AND MOLECULES
Clifford R Jack Jr , David S Knopman , William J Jagust , Ronald C Petersen , Michael W Weiner , et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers The Lancet Neurology Volume 12, Issue 2 2013 207 - 216
3/2/2017
12
Age-related Brain Network Stress
Compensation
Amyloid
Tau-related Neurodegeneration
Normal Aging
Alz
hei
mer
’s D
isea
se
Mild
Cog
nitiv
e Im
pairm
ent
Dem
entia
HOW DO WE ROBUSTLY MEASURES AN
INDIVIDUALS LARGE-SCALE BRAIN PATTERNS?
http://www.humanconnectome.org/
This individual spent 7% of 20 minute resting task-free functional MRI brain
scanning session in a large-scale brain configuration that looks like this.
3/2/2017
13
IMAGING BIOMARKERS: MEASURING MINDS AND
MOLECULES
• A biological marker of some state.
• National Institutes of Health Biomarkers Definitions Working Group:
• “[A] characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention.”
• How can we use biomarkers?
• Diagnosis
• Prognosis
• Monitor progression
• Monitor disease response to therapeutic interventions
• Understand pathophysiology (i.e. the cause of the disease)
Mayo Clinic Alzheimer’s Disease Research Center (ADRC)
Mayo Clinic Study of Aging (MCSA) (PI: Ron Petersen)
Aging and Dementia Imaging Research Laboratory (PI: Cliff Jack)